Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 3/20 | 0.57 |
| ▸ | KISS1R | Q969F8 | 8/20 | 0.50 |
| ▸ | MAGI3 | Q5TCQ9 | 1/20 | 0.47 |
| ▸ | MC4R | P32245 | 2/20 | 0.46 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.45 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.45 |
| ▸ | ITGAL | P20701 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31001649 | 0.93 | GHSR (0.57) | GHSRKISS1RMC4RITGB2ICAM1 | |
| SCHEMBL30544310 | 0.90 | GHSR (0.58) | GHSRKISS1R | |
| SCHEMBL29994188 | 0.90 | GHSR (0.57) | GHSRKISS1R | |
| SCHEMBL31606511 | 0.90 | GHSR (0.59) | GHSRKISS1RMC4RITGB2ICAM1 | |
| SCHEMBL30866241 | 0.90 | GHSR (0.62) | GHSRKISS1R | |
| SCHEMBL31026129 | 0.89 | GHSR (0.60) | GHSRKISS1R | |
| SCHEMBL29895432 | 0.89 | GHSR (0.53) | GHSRITGB2ICAM1ITGAL | |
| SCHEMBL29426615 | 0.88 | GHSR (0.65) | GHSRITGB2ICAM1ITGAL | |
| SCHEMBL30051294 | 0.88 | GHSR (0.65) | GHSRITGB2ICAM1ITGAL | |
| SCHEMBL29615300 | 0.88 | GHSR (0.59) | GHSRKISS1RMC4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260098072-A1 | METHODS OF STIMULATING APPETITE AND/OR INCREASING BODY WEIGHT USING NON-NATURALLY OCCURRING MELANOCORTIN RECEPTOR ANTAGONIST ANALOGS | ENDEVICA BIO INC (US) | 2026-04-09 | — | — | US | disclosed |
| EP-4605407-A2 | METHODS OF STIMULATING APPETITE AND/OR INCREASING BODY WEIGHT USING NON-NATURALLY OCCURRING MELANOCORTIN RECEPTOR ANTAGONIST ANALOGS | Endevica Bio, Inc. (US) | 2025-08-27 | — | — | EP | disclosed |
| WO-2025151135-A1 | METHODS OF TREATING CANCER AND/OR CHEMOTHERAPY RELATED CONDITIONS USING NON-NATURALLY OCCURRING MELANOCORTIN ANALOGS | ENDEVICA BIO, INC. (US) | 2025-07-17 | — | — | WO | disclosed |
| WO-2024177909-A1 | METHODS OF STIMULATING APPETITE AND/OR INCREASING BODY WEIGHT IN SUBJECTS HAVING A FIBROTIC DISEASE USING NON-NATURALLY OCCURRING MELANOCORTIN ANALOGS | ENDEVICA BIO, INC. (US) | 2024-08-29 | — | — | WO | disclosed |
| WO-2024086381-A2 | METHODS OF STIMULATING APPETITE AND/OR INCREASING BODY WEIGHT USING NON-NATURALLY OCCURRING MELANOCORTIN RECEPTOR ANTAGONIST ANALOGS | ENDEVICA BIO, INC. (US) | 2024-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260098072-A1 | METHODS OF STIMULATING APPETITE AND/OR INCREASING BODY WEIGHT USING NON-NATURALLY OCCURRING MELANOCORTIN RECEPTOR ANTAGONIST ANALOGS | MC1R, MC4R, MC5R | GHSR 13/4885KISS1R 154/4885MAGI3 2971/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.